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Abstract
Loss-of-function mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene have been identified in
patients with heritable pulmonary arterial hypertension (PAH); however, disease penetrance is low, suggesting additional
factors play a role. Inflammation is associated with PAH and vascular remodeling, but whether allergic inflammation triggers
vascular remodeling in individuals with BMPR2 mutations is unknown. Our goal was to determine if chronic allergic
inflammation would induce more severe vascular remodeling and PAH in mice with reduced BMPR-II signaling. Groups of
Bmpr2 hypomorph and wild-type (WT) Balb/c/Byj mice were exposed to house dust mite (HDM) allergen, intranasally for 7
or 20 weeks to generate a model of chronic inflammation. HDM exposure induced similar inflammatory cell counts in all
groups compared to controls. Muscularization of pulmonary arterioles and arterial wall thickness were increased after 7
weeks HDM, more severe at 20 weeks, but similar in both groups. Right ventricular systolic pressure (RVSP) was measured by
direct cardiac catheterization to assess PAH. RVSP was similarly increased in both HDM exposed groups after 20 weeks
compared to controls, but not after 7 weeks. Airway hyperreactivity (AHR) to methacholine was also assessed and
interestingly, at 20 weeks, was more severe in HDM exposed Bmpr2 hypomorph mice versus WT. We conclude that chronic
allergic inflammation caused PAH and while the severity was mild and similar between WT and Bmpr2 hypomorph mice,
AHR was enhanced with reduced BMPR-II signaling. These data suggest that vascular remodeling and PAH resulting from
chronic allergic inflammation occurs independently of BMPR-II pathway alterations.
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Introduction
Pulmonary arterial hypertension (PAH) is a devastating disease
characterized by vascular dysfunction and remodeling. Arterial
remodeling causes increased pulmonary vascular resistance,
resulting in sustained pulmonary artery pressures that lead to
right ventricular hypertrophy and subsequently death due to right-
sided heart failure [1–9]. Although PAH is a rare disease, once
diagnosed, life expectancy is generally less than three years in
adults [4,6] and less than 1 year in children [10] without
therapeutic interventions. Despite intense investigation into the
pathogenesis of PAH, the etiology remains unclear and present
therapies only slow disease progression [2,4,10].
Some insight into the pathogenesis of PAH has come from the
discovery that heterozygous mutations in the bone morphogenetic
protein receptor type 2 gene (BMPR2) are present in many
patients with heritable pulmonary arterial hypertension (PAH) and
some patients with idiopathic PAH [1,11–15]. The BMPR2 gene
encodes the bone morphogenetic protein receptor type II (BMPR-
II), which is a member of the transforming growth factor-b
superfamily and plays a critical role in embryogenesis, apoptosis,
cell growth, and cell differentiation. Upon ligand binding, the
type I BMP receptor is activated by BMPR-II, causing
phosphorylation and activation of downstream signaling mole-
cules, Smads 1, 5 and 8 [16–19]. While approximately 70% of
patients with heritable PAH have mutations in the BMPR2 gene,
the disease penetrance is low, with some reports showing that only
,10–20% of family members with BMPR2 mutations actually
develop symptomatic PAH [1,5–7,13,14]. As a result, it has been
suggested that other genetic and/or environmental factors may be
necessary for clinical expression of PAH in individuals with
BMPR2 mutations [14].
PAH is known to occur in diseases in which inflammation is a
cardinal feature (i.e. autoimmune diseases and HIV infection),
leading to the suggestion that inflammation may be an important
mediator or trigger of pulmonary arterial remodeling [3,20]. In
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increases in inflammatory cells in the vicinity of remodeled vessels,
as well as elevated levels of pro-inflammatory cytokines such as IL-
1b and IL-6 [2,20–22]. Experimental studies in mice and rats have
shown that inflammatory models such as chronic hypoxia [23,24],
monocrotaline [21,25,26], and allergic asthma (ovalbumin,
Aspergillus fumigatus, house dust mite) [3,27,28] all develop varying
degrees of vascular remodeling. These data further support a role
for inflammatory pathways in vascular remodeling and disease,
however, the exact involvement of these pathways remains poorly
defined.
Given the potential role of inflammation in vascular remodeling
[3,21,23–27] and the development of PAH in patients with
BMPR2 mutations [1,11–15], we hypothesized that chronic
inflammation would trigger more severe arterial remodeling and
PAH in mice with reduced BMPR-II signaling. To address this
question we utilized Bmpr2 hypomorph mice, as Bmpr2 null mice
die during early gastrulation [29]. Bmpr2 hypomorph mice have a
deletion in exon 2 (hereafter referred to as Bmpr2 DE2 mice) that
encodes half of the extracellular ligand-binding domain of the
receptor [30]. This deletion results in reduced BMPR-II signaling
[30] similar to that seen in patients with BMPR2 mutations [4].
Bmpr2 DE2 mice that are homozygous for the hypomorphic allele
die during mid-gestation with cardiovascular and skeletal defects:
however, mice that are heterozygous for the hypomorphic allele
develop into adulthood with no apparent abnormalities [30]. In
this study, we exposed wild-type (WT) and Bmpr2 DE2 mice to the
aeroallergen, house dust mite (HDM), for 7 or 20 weeks to induce
chronic inflammation, as previous studies had reported vascular
remodeling in WT mice following such a protocol [27].
Muscularization of pulmonary arterioles and right ventricular
systolic pressures (RVSP) were measured to assess the severity of
vascular remodeling and PAH after chronic inflammation in
both groups. Additionally, airway hyperreactivity (AHR) was
assessed as part of the allergic response and to assess airway
function since a study had reported reduced BMPR-II expression
in the airways of patients with asthma [31]. Vascular remodeling
and mild PAH developed after 20 weeks of HDM in both Bmpr2
DE2 and WT mice; however, there was no difference between
these groups. Interestingly, AHR was more severe after 20 weeks
of HDM exposure in Bmpr2 DE2 mice compared to WT,
demonstrating a phenotypic difference in these mice. These results
suggest that vascular remodeling and PAH resulting from chronic
allergic inflammation occurs independently of Bmpr2 mutations.
The exaggerated AHR in Bmpr2 DE2 mice suggests a potential
role for this pathway as a modifier of chronic allergic airway
disease.
Results
Genotype Analysis of DNA from Bmpr2 DE2 Mice
To verify the genotype of the mice, PCR of tail DNA from WT
and Bmpr2 DE2 mice was performed using primer probe sets
specific for both the WT and hypomorph alleles. WT and Bmpr2
DE2 mice were distinguishable by the amplification of a 450-bp
fragment for the hypomorph allele (Figure 1A).
Alterations in BMPR-II Signaling in Response to
HDM. To determine if signaling downstream of BMPR-II was
altered in response to HDM, western blot analysis for
phosphorylated Smad1/5 (P-Smad1/5) was performed on lung
homogenates of saline and HDM exposed WT mice. P-Smad1/5
levels were reduced by approximately 50% in mice exposed to
HDM for 20 weeks compared to saline controls (Figure 1B).
Inflammatory cell response and Immunoglobulin Levels
after HDM Exposure
Total inflammatory cells were assessed in the BALF. Increases
in total inflammatory cell counts were similar in HDM exposed
WT and Bmpr2 DE2 mice, at both 7 and 20 weeks (Figure 2A).
Specific inflammatory cell types were assessed by Diff-Quick
staining of cytospins. Representative images are shown in
Figure 2B. Total neutrophil and eosinophil numbers were
increased after 7 weeks of HDM exposure compared to saline
controls. After 20 weeks of HDM, neutrophil and eosinophil
numbers were still increased above controls although total
eosinophil numbers were lower compared to 7 weeks (Figure 2C).
In addition, the percentage of neutrophils and eosinophils were
increased in WT and Bmpr2 DE2 mice after 7 and 20 weeks of
HDM exposure compared to saline controls (Table 1). Lympho-
cytes percentages were increased only in HDM treated Bmpr2
DE2 mice at 7 weeks, but similarly increased in both WT and
Bmpr2 DE2 at 20 weeks. The percentage of eosinophils was lower
and the percentage of neutrophils was increased after 20 weeks of
HDM compared to 7 weeks. HDM specific IgG1 and IgE levels
were measured after HDM exposure to assess sensitization to the
allergen. HDM specific IgG1 and IgE levels were similarly
increased in HDM exposed WT and Bmpr2 DE2 groups
compared to saline controls after 7 (top panels) and 20 (bottom
panels) weeks (Figure 3). HDM specific IgG1 was slightly higher
(1.3 fold) in WT mice compared to Bmpr2 DE2 mice after 7 weeks
of HDM exposure, but not after 20 weeks. Increases in HDM
Figure 1. Genotype analysis of Bmpr2 hypomorph allele and
levels of P-Smad1/5 in HDM exposed mice. A: Tail DNA from mice
carrying the wild-type (WT) and/or the Bmpr2 hypomorph (DE2) alleles
were genotyped by PCR using the primers Bmpr2 MT Neo R1 to detect
the hypomorph allele (DE2 450 bp) and Bmpr2 WT R2 to detect the WT
allele (WT 230 bp). PCR products were run on a 4% agarose gel
containing ethidium bromide and photographed. B: Western blot
analysis of P-Smad1/5, a downstream mediator of BMPR-II signaling,
was decreased by approximately 50% after HDM exposure compared to
saline controls (n=5 mice/group). *P,0.05 vs saline.
doi:10.1371/journal.pone.0032468.g001
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Pulmonary Vascular Remodeling
No differences in thickening of the arterial wall of the small
pulmonary arteries were detected between saline exposed WT and
Bmpr2 DE2 mice (Figure 4A). Animals exposed to HDM for 7 or
20 weeks demonstrated increased thickening of the medial layer in
small pulmonary arteries (20–150 mm) in both WT and Bmpr2
DE2 mice compared to saline controls (Figure 4A). Vessel wall
thickness was measured by morphometric analysis as demonstrat-
ed in Figure 4B. Morphometric analysis revealed significant
increases in wall thickness after HDM exposure; however, they
were similar between WT and Bmpr2 DE2 mice at 7 and 20 weeks
(Figure 4C). Mice exposed to HDM had a higher percentage of
fully muscularized vessels compared to saline treated controls at
both 7 and 20 weeks (Figure 5B). The percentage of fully
muscularized vessels was further increased after 20 weeks of HDM
exposure compared to 7 weeks. This pattern of muscularization
was similar between HDM exposed WT and Bmpr2 DE2 mice at
both time points. In addition to the increases in percentages of
muscularized vessels, the total number of muscularized vessels
(fully+partially together) was increased in HDM exposed mice
compared to saline controls (data not shown).
Pulmonary Arterial Hypertension
Right heart catheterization was performed to assess the
development of PAH. In animals exposed to 7 weeks of HDM,
no increase in right ventricular systolic pressure (RVSP) in either
group was detected compared to saline controls (data not shown).
Figure 2. Inflammatory cell response in HDM exposed mice. A: Total inflammatory cell counts were increased in BALF in both WT (white bars)
and Bmpr2 DE2 (DE2; black bars) mice after 7 weeks (wk) and 20 weeks of HDM (n=4–13 mice/group in two independent experiments). *P,0.05 vs
saline control, ‘P,0.05 vs saline WT 20 weeks. B: Representative images of cytospins from BALF demonstrating specific inflammatory cell types in the
lung after 7 and 20 weeks of saline or HDM exposure. The inset in the top panel shows a high power image of an eosinophil and the bottom panel
inset is a representative image of a neutrophil. M=Macrophage, L=Lymphocyte, N=Neutrophil, and E=Eosinophil. Scale bar larger panels=20 mm.
Insets scale bar=10 mm. C: Changes in macrophage cell numbers were only observed after 20 weeks of HDM and only in BMPR2 DE2 mice.
Neutrophils and eosinophil numbers were increased in HDM exposed groups at both time points, however, the number of eosinophils was lower
after 20 weeks. *P,0.05 vs saline control, ‘P,0.05 vs saline DE2 lymphocyte 20 weeks, #P,0.05 vs saline WT macrophage 20 weeks, +P,0.05 vs
HDM WT macrophages 20 weeks, @P,0.05 vs HDM WT neutrophil 20 weeks.
doi:10.1371/journal.pone.0032468.g002
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increased in WT (33.5461.57 versus 26.3461.11) and in Bmpr2
DE2 (30.4160.76 versus 26.6760.51) mice compared to saline
controls indicating the development of mild PAH in these animals
(Figure 6A). RVSP was not different between HDM exposed
Bmpr2 DE2 mice and WT mice (30.4160.76 versus 33.5461.57).
Although RVSP was increased in both HDM exposed WT and
Bmpr2 DE2 mice after 20 weeks, the RV to LV+S weight ratio
was only increased in Bmpr2 DE2 mice compared to saline
controls (0.3160.01 versus 0.2760.01) (Figure 6B). However,
there was no difference between the RV to LV+S weight ratio in
HDM exposed WT and Bmpr2 DE2 mice (0.3260.02 versus
0.3160.01).
Airway Hyperreactivity
After RVSP measurements were obtained, airway hyperreac-
tivity (AHR) to increasing doses of methacholine was assessed since
it had been previously reported that Bmpr2 expression was
decreased in asthmatic patients [31]. After 7 weeks of HDM
exposure, AHR was similarly increased in both WT and Bmpr2
DE2 mice compared to saline controls (data not shown). After 20
weeks of HDM exposure, AHR was increased in both WT and
Bmpr2 DE2 compared to saline controls. Interestingly though,
after 20 weeks, AHR was more severe in the HDM exposed
Bmpr2 DE2 mice at both 25 mg/ml (2.4 fold) and 50 mg/ml (1.8
fold) methacholine compared to the HDM exposed WT mice
(Figure 7).
Figure 3. Allergic sensitization in HDM exposed mice. Levels of HDM specific IgG1 and IgE were increased in both WT and Bmpr2 DE2 mice
after 7 weeks (top panels) and 20 weeks (bottom panels) of HDM exposure. At 7 weeks, HDM specific IgG1 levels in WT mice were slightly higher
compared to Bmpr2 DE2 mice (n=4–12 mice/group). *P,0.05 vs saline control, ‘P,0.05 vs HDM WT 7 weeks.
doi:10.1371/journal.pone.0032468.g003
Table 1. Percentage of inflammatory cells in BALF of WT and
Bmpr2 DE2 mice after saline or HDM exposure.
Macrophages Lymphocytes Neutrophils Eosinophils
7 wks HDM
WT Saline 99.762.4% 0.060.0% 4.062.2% 0.360.2%
DE2 Saline 98.260.4% 0.160.1% 1.660.3% 0.160.1%
WT HDM 28.364.8%* 1.660.5% 17.363.5%* 52.966.5%*
DE2 HDM 35.565.3%* 3.460.7%* 17.261.5%* 44.064.8%*
20 wks HDM
WT Saline 97.761.7% 0.860.4% 2.661.1% 0.160.1%
DE2 Saline 91.762.0%# 0.660.2% 7.661.9%@ 0.160.0%
WT HDM 34.763.2%* 7.861.8%* 31.862.0%* 24.662.6%*
DE2 HDM 41.962.7%* 8.061.5%* 32.462.1%* 17.861.7%*‘
Increases in the percentage of neutrophils and eosinophils were observed in
both HDM exposed wild-type (WT) and Bmpr2 DE2 (DE2) mice after 7 wk of
HDM compared to saline controls. Lymphocytes were also increased after 7 wk
of HDM exposure in Bmpr2 DE2 mice. Lymphocytes, neutrophils, and
eosinophils were all increased after 20 wk of HDM exposure compared to saline
controls. Data are presented as mean 6 SEM. N=4–12 mice per group in two
independent experiments.
*P,0.05 vs saline controls,
‘P,0.05 vs WT HDM 20 wk eosinophils,
#P,0.05 vs WT saline 20 wk macrophages,
@P,0.05 vs WT saline 20 wk neutrophils.
doi:10.1371/journal.pone.0032468.t001
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The present study demonstrates that while mice exposed to the
aeroallergen HDM for 7 weeks develop increases in wall thickness
and muscularization of pulmonary arterioles, this was not
associated with significant increases in RVSP. However, when
HDM exposure was extended out to 20 weeks, arterial remodeling
was more severe and RVSP was significantly increased, although
mild. Despite these increases in RVSP and arterial remodeling,
Bmpr2 DE2 mice showed similar responses to WT mice,
suggesting that reductions in BMPR-II signaling do not predispose
for more severe PAH with chronic allergen-induced inflammation.
Although vascular changes were similar between Bmpr2 DE2 and
WT mice, AHR in Bmpr2 DE2 mice was more severe after 20
weeks HDM which suggests a potential role for this pathway as a
modifier of reactive airway disease.
Previous studies have examined the role of inflammation and
chronic hypoxia in the development of PAH in Bmpr2
heterozygous mice (Bmpr2
+/2). Zhang et. al. treated Bmpr2
+/2
mice with adenovirus-delivered 5-lipoxygenase (5-LO), which is
known to facilitate inflammation and is increased in patients and
animal models of PAH [32,33]. These studies demonstrated
Figure 4. Vascular remodeling and arterial wall thickness following chronic HDM exposure. A: a-Smooth muscle actin (a-SMA) staining
was performed on lung sections from WT (top) and Bmpr2 DE2 (DE2; bottom) mice exposed to saline or HDM for 7 or 20 weeks (wk). Thickening of
the arterial wall (medial layer) in HDM exposed mice is seen (arrows) at both 7 and 20 weeks. Scale bar larger panels=200 mm. Insets scale
bar=50 mm. B: Image of a-SMA immunostaining of a pulmonary artery demonstrating the method used to measure arterial wall thickness. For each
vessel, external diameter and two wall thicknesses were measured along two different axes. Percent wall thickness was calculated as [(1a+1b)/
external diameter]6100. This measurement was performed along each axis. The two axes measurements were averaged together to determine the
final wall thickness. C: Percent wall thickness of pulmonary arteries (20–150 mm) was increased 1.5 fold in HDM exposed mice after 7 weeks (wk) and 2
fold in mice exposed to HDM for 20 weeks. Differences between WT (white bars) and Bmpr2 DE2 (DE2) (black bars) mice exposed to saline or HDM
were not significant (n=5–13 mice/group). *P,0.05 vs saline control.
doi:10.1371/journal.pone.0032468.g004
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+/2 mice
compared to WT; however, the degree of muscularization in the 5-
LO treated mice was mild [34]. A subsequent study demonstrated
that Bmpr2
+/2 mice treated with combined 5-LO and monocro-
taline developed sustained increases in RVSP, thickening of small
pulmonary arteries, and perivascular inflammation of the
remodeled vessels that was more severe in Bmpr2
+/2 mice
compared to WT [26]. Another study utilizing Bmpr2
+/2 mice,
found that a combination of hypoxia and chronic serotonin
infusion increased RVSP, right ventricular hypertrophy, and
pulmonary remodeling [35]. In the present study, we utilized
HDM, as many people develop allergic responses this common
aeroallergen [27,36,37]. In addition, Erjefalt et. al. had previously
demonstrated that chronic HDM exposure could cause pulmonary
vascular modeling in mice after 20 weeks of HDM; however, no
direct measures of PAH were reported [27]. Unlike reports
mentioned earlier, in the present study, PAH severity was not
enhanced in BMPR2 mutant mice compared to WT mice. This
discrepancy may be due to the different types of inflammation
induced in the previous studies since they primarily elicit Th1
responses and little to no eosinophils [20,24,26]. In contrast to
previous models, HDM exposure induces the release of Th2
cytokines (interleukin 4 (IL-4), IL-5, and IL-13) and an influx of
eosinophils during acute exposures and neutrophils during chronic
exposures [27,38–42]. A role for Th2 cytokines in the etiology of
vascular remodeling was demonstrated by Grunig et. al. as
pulmonary arterial remodeling in OVA and Aspergillus fumigatus
exposed mice was reduced in IL-4 deficient mice. Comparing the
findings of our study to others, suggests that the type of stimuli may
be important in determining whether PAH is more severe or not in
BMPR2 mutant mice. In addition, in some of these studies, more
than one insult was required for animals with reduced BMPR2 to
show any PAH phenotype [26,35], suggesting that the develop-
ment of the disease may be multi-factorial. This is consistent with
additional genetic and/or environmental factors being necessary
to trigger PAH in patients with BMPR2 mutations since the
penetrance of the disease is low.
In the present study, we assessed vascular remodeling and
RVSP after 7 and 20 weeks of HDM exposure to determine if the
changes in arterial remodeling were associated with PAH. In
addition, we examined the question of whether a Bmpr2 signaling
deficiency in HDM exposed mice would cause more severe
pulmonary arterial remodeling changes, since mutations in this
gene are found in 70% of patients with heritable PAH. Although
increases in arterial muscularization in HDM exposed mice were
observed after 7 weeks, RVSP was not increased. However, after
20 weeks of HDM exposure, RVSP was similarly increased in both
WT and Bmpr2 DE2 mice in conjunction with more severe
Figure 5. Muscularization of small pulmonary arteries. A: Representative images of a-SMA immunostaining of non-muscular (NM), partially
muscularized (PM) [53], and fully muscularized (FM) small arterioles used to determine percent muscularization of vessels after HDM exposure (406).
B: WT and Bmpr2 DE2 (DE2) mice demonstrated increases in the number of arterioles that were fully muscularized (FM) and fewer arterioles that were
non-muscular (NM) compared to saline controls after 7 weeks (wk) HDM (left). The percentage of FM arterioles was further enhanced after 20 weeks
of HDM and the proportion of NM arterioles was further reduced. No differences were detected between groups of WT and Bmpr2 DE2 mice exposed
to saline or HDM (n=5–13 mice/group). *P,0.05 vs saline control, ‘P,0.05 vs DE2 saline PM.
doi:10.1371/journal.pone.0032468.g005
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studies which showed that persistent allergic inflammation could
induce pulmonary vascular remodeling [3,27], however; in
addition, we were able to detect PAH, although mild. The
development of PAH in our model might be partly due to a higher
percentage of fully muscularized pulmonary arteries at 20 weeks
compared to 7 weeks; however, factors such as vasoconstriction
could also be playing a role in the pathophysiology.
Although an increase in the number of inflammatory cytokines,
macrophages, T cells, B cells, and chemokines have been observed
in patients with PAH, the exact role of these molecules in the
disease process is unclear [3,22,43,44]. As previously mentioned,
Grunig et al. [3], exposed mice to ovalbumin and Aspergillus
fumigatus for extended periods of time, and found that both of these
allergens caused pulmonary arterial remodeling; however, in-
creased muscularization of the pulmonary arteries did not
correlate with RVSP measurements. A more recent study by
Morrell et al. reported severe pulmonary arterial remodeling in the
presence of Th1 and Th2 inflammatory responses in a mouse
model of schistosomiasis, which is thought to be a common cause
of pulmonary hypertension [45]. PAH was not observed in these
mice, even though extensive pulmonary arterial remodeling was
detected. In contrast to the studies above, we were able to detect
increases in RVSP after inducing chronic inflammation in our
model of vascular remodeling. Recent reports indicate that both
mouse strain and sex can affect the inflammatory responses
[46,47]. It is possible that the strain of mice used (Balb/c/Byj) in
this study may have influenced the response to chronic
inflammation differently compared to the other studies since mice
of a different background were used (C57BL/6) [3,26,35].
Although differences in sex have previously been shown to affect
the inflammatory response, we were unable to detect any
differences in inflammation or RVSP between males and females
in our model; however, there was a trend towards higher RVSP in
females.
In addition to vascular remodeling and PAH, we also assessed
AHR in our model since a study reported decreased BMPR2 in
the airways of asthmatic patients, providing evidence for a
potential role for the BMPR2 pathway in allergic asthma [31].
Interestingly, in our study, more severe AHR was observed in
Bmpr2 DE2 mice after 20 weeks of HDM exposure compared to
WT mice. These findings offer further support that this pathway
may be a modifier of the asthmatic response, although additional
studies are needed to address this more extensively. Prior to this
study, there had been little evidence suggesting any common
features between PAH and asthma. One case report showed both
increased pulmonary pressures and reactive airway disease in two
patients with congenital heart disease [48]. After long-term
treatment of these patients for the asthma symptoms, pulmonary
pressures decreased; however, whether these two diseases are
linked is unclear. One explanation for the lack of information
regarding any connection between these two diseases may be due
to the fact that the PAH patient population is small.
In summary, we demonstrated that chronic HDM exposure
causes arterial remodeling and PAH in mice, although we were
unable to detect any differences in the response between WT and
Figure 6. Pulmonary arterial hypertension following chronic
HDM exposure. A: Right ventricular systolic pressures (RVSP) was
increased in both WT and Bmpr2 DE2 (DE2) mice after HDM exposure
for 20 weeks compared to saline controls. There was no difference in
RVSP between WT and Bmpr2 DE2 mice exposed to HDM (n=4–11
mice/group in two independent experiments). *P,0.05 vs saline
control. B: The ratio of RV weight to LV+S weight was only increased
in Bmpr2 DE2 mice compared to saline controls (n=4–11 mice/group in
two independent experiments). *P,0.05 vs saline control.
doi:10.1371/journal.pone.0032468.g006
Figure 7. Airway hyperreactivity following chronic HDM
exposure. Bmpr2 DE2 mice developed more severe airway respiratory
resistance to methacholine after 20 weeks of HDM compared to WT
mice (n=4–12 mice/group). Both HDM groups demonstrated increased
airway resistance with methacholine exposure compared to saline
controls. *P,0.05 vs saline controls, ‘P,0.05 vs WT HDM.
doi:10.1371/journal.pone.0032468.g007
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causes vascular remodeling and PAH through mechanisms that
may be independent of the BMPR-II signaling pathway. To our
knowledge, this is the first study to establish that chronic allergen
exposure causes PAH, albeit mild. Additionally, we observed more
severe AHR in Bmpr2 DE2 mice compared to WT after chronic
HDM exposure, suggesting a potential role for Bmpr2 in allergic
airway disease.
Methods
Ethics statement, animal treatments, and RVSP
measurements
Animal protocols and procedures were approved by the Animal
Care and Use Committee at the Cincinnati Children’s Hospital
Research Foundation (Cincinnati, OH) (Protocol Number:
1D02011) and all procedures were performed under anesthesia
to minimize suffering. Bmpr2 DE2 heterozygous mice were
generated by Dr. Karen Lyon’s lab (UCLA, Los Angeles) [30].
At Cincinnati Children’s Hospital, mice were bred onto a mixed
Balb/c/Byj background, since this strain responds well to allergens
and is frequently used in allergic inflammatory models. All WT
mice used were littermate controls from these breedings.
At 6–10 weeks of age, WT and Bmpr2 DE2 mice were exposed
intranasally to either 20 ml saline (0.9% NaCl) (vehicle control
group) or 25 mg of the allergen, house dust mite (HDM) (Greer
Laboratories, Lenoir, NC), dissolved in 20 ml of saline, 3 times per
week and for either 7 or 20 weeks. Isoflurane was used to
anesthetize the mice during repeated intranasal HDM exposures.
At the end of the treatment periods, mice underwent right heart
catheterization, as previously described [34]. Briefly, mice were
anesthetized with 2.5% isoflurane and remained sedated with
,2.0–2.25% isoflurane via a nose cone during catheterization.
After dissection to expose the right jugular vein, an SPR-671
pressure transducer catheter (Mikro-Tip 1.4F, Millar Instruments,
Houston, Texas) was inserted into the jugular vein via a small
incision, passed through the right atrium and into the right
ventricle where right ventricular systolic pressures (RVSP) were
measured. For each mouse, an average of 30 individual RVSP
measurements during a 3–5 minute time period were taken and
analyzed using the HSE Haemodyn W software (version
1.1.1.131, Harvard Apparatus).
Genotype Analysis
Genotypes were determined by PCR (Figure 1) with the primer
Bmpr2 WT R2 to detect the wild-type allele (230-bp) and Bmpr2
MT Neo R1 used to detect the neo cassette, which was inserted in
place of exon 2 to generate a hypomorph allele (450-bp). Another
primer, Bmpr2 F2, was used as a forward primer for both sets of
reactions. Amplification was performed for 34 cycles with
1 minute at 95uC, 1 minute at 56uC, and 1 minute at 72uC.
The sequences for the primers were: Primer Bmpr2 MT Neo R1,
59 CCTTCTATCGCCTTCTTGAC 39; Primer Bmpr2 WT R2
59 TTCCCTGATAACAGCCTTCC 39; Primer Bmpr2 F2 59
AAGTACACGGTCGCTGTCTTC 39.
Western Blot Analysis
Western blot analysis was performed on lung homogenates
using the following antibodies to assess the levels of phosphory-
lated Smad1/5 (P-Smad1/5, 1:1,000; Cell Signaling) and b-
tubulin (1:1,000; Cell Signaling). A goat anti-rabbit secondary
antibody (1:10,000; Calbiochem) was used along with an ECL plus
chemiluminescence detection system (GE Heathcare). An
LAS4000 imaging system and Multi Gauge 3 software (Fujifilm,
Tokyo, Japan) were used to image and quantitate the chemilumi-
nescent signal for each Western blot. Protein loading and transfer
efficiency were controlled for each sample by normalizing to b-
tubulin.
Airway Hyperreactivity
After RVSP measurements, mice were anesthetized with an
intraperitoneal injection of Ketamine/Xylaxine/Acepromazine
(4:1:1) solution and changes in airway resistance to methacholine
were assessed as previously described [49]. Briefly, after a
tracheostomy was performed, the mouse was connected to a
flexiVent system (SCIREQ, Montreal, QC, Canada). Airway
respiratory resistance was measured after nebulization of phos-
phate buffered saline (16PBS) (baseline) and then increasing doses
of methacholine (12.5, 25, and 50 mg/mL; acetyl-b-methylcholine
chloride, Sigma, St. Louis, MO).
Bronchoalveolar lavage
After AHR measurements were performed, bronchoalveolar
lavage fluid (BALF) was collected from mice to assess the
inflammatory response. Lungs were lavaged three times via a
tracheostomy tube with a total volume of 1 ml of 16 PBS as
previously described [49]. The BALF was centrifuged (2000 RPM)
and the supernatant was removed and used to measure HDM
specific IgE and IgG1 levels. Red blood cell lysis buffer (R7757
Sigma, St. Louis, MO) was added to the cell pellet to lyse any red
blood cells. Cells were centrifuged again, supernatant removed,
and cells resuspended in PBS. Total inflammatory cells were
counted using a hemocytometer. Cytospins of the remaining cells
were collected on slides for differential cell counts. Inflammatory
cell types were determined by Diff-Quick staining (Shandon
Lipshaw, Pittsburg, PA) (Figure 2B). Three hundred cells were
counted per slide and the percentages of macrophages, lympho-
cytes, neutrophils, and eosinophils were determined.
ELISA
HDM specific IgG1 and IgE levels were measured in BALF by
ELISA to assess allergic sensitization to HDM as previously
described [50]. Briefly, plates were coated with 0.01% HDM in
PBS overnight. The following day, plates were blocked with 1%
BSA in PBS for 1 hour then coated with samples. Biotin-anti-
mouse IgE or IgG1 (Pharmingen, 2.0 mg/ml) was used for capture.
Streptavidin-HRP (1:100, R & D, Minneapolis, MN) was added to
detect antibodies and the reaction developed by TMB substrate
(1:1) (BD Biosciences, San Jose, CA).
Immunohistochemistry and arterial remodeling
Lungs were inflation fixed by tracheal installation of 4%
paraformaldehyde at constant pressure (25 cmH2O), transferred
to 70% ethanol after 24 hrs, cut into three sections, and embedded
in paraffin as previously described [51]. Immunostaining for a-
smooth muscle actin (a-SMA) was performed on 5 mm paraffin-
embedded sections by incubating slides with an a-SMA monoclo-
nal antibody (1:10,000 dilution, Clone 1A4; Sigma) overnight at
4uC, followed by a goat anti-mouse IgG2a secondary antibody
(1:200, Southern Biotech, Birmingham, AL). A Zeiss Axioplan 2
microscope (Carl Zeiss Microimaging, Thornwood, NY) was used
to obtain digital images of the immunostaining. All genotypes and
identification numbers of the animals were blinded to the observer,
and the images were randomized. Vessel wall thickness was
measured on pulmonary arteries with an external diameter
ranging from 20–150 mm that were associated with terminal
bronchioles and fully muscularized. The total number of vessels
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software (v6.2; Universal Imaging/Molecular Devices, Down-
ington, PA) was used to measure the medial wall thickness and
external diameter of each vessel. For each vessel, wall thickness
and the external diameter were measured twice, along two
different axes (Figure 4B). Percent wall thickness was calculated as
[(wall 1a thickness+wall 1b thickness)/external diameter 1]6100.
This calculation was performed for each axis. Each axis
measurement was averaged together to determine the final wall
thickness. Four to six vessels were measured for each animal. In
addition to wall thickness measurements, percent muscularization
of the pulmonary arterioles was also assessed. Small pulmonary
arterioles in the terminal bronchial and the alveolar regions were
identified and scored for muscularization as previously described
[52]. Briefly, vessels were scored as nonmuscular (NM) (,50%
muscle around vessel), partially muscularized (PM) [53] (.50%
but ,100% muscle surrounding the vessel), or fully muscular (FM)
(muscle surrounds 100% of vessel) (Figure 5A). Thirty small
pulmonary arteries were scored per animal and expressed as a
percentage of total vessels counted.
Statistical Analysis
Statistical analysis was performed with Prism 4 software
(GraphPad Software, San Diego, CA). Unpaired t-tests, one-way,
and two-way ANOVA with Tukey’s post-hoc test were used to
make comparisons. P,0.05 was considered statistically significant.
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